Tonix Pharmaceuticals Q3 net loss widens

Reuters11-11

Tonix Pharmaceuticals Q3 net loss widens

Overview

Tonix Q3 net loss widens to $32 mln
Company to launch Tonmya for fibromyalgia in November, first new treatment in 15 years
Tonix in-licenses TNX-4800 for Lyme disease, plans Phase 2/3 study in 2027

Outlook

Tonix expects cash reserves to fund operations into Q1 2027
Tonmya launch set for November 2025 with commercial infrastructure in place
Company plans to initiate TNX-4800 study during tick season in 2027

Result Drivers

Research and development expenses for the three months ended September 30, 2025 were $9.3 million, compared to $9.1 million for the same period in 2024.

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income		-$32.01 mln
Q3 Operating Income		-$33.07 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Tonix Pharmaceuticals Holding Corp is $68.00, about 75% above its November 7 closing price of $17.00

Press Release: ID:nGNX6KCDn

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582388748?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 05:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582388748","market":"nz","top_or_hot":-1,"title":"Tonix Pharmaceuticals Q3 net loss widens","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Tonix Pharmaceuticals Q3 net loss widens </title></head><body><p><span>Overview</span></p><ul><li><p>Tonix Q3 net loss widens to $32 mln</p></li><li><p>Company to launch Tonmya for fibromyalgia in November, first new treatment in 15 years</p></li><li><p>Tonix in-licenses TNX-4800 for Lyme disease, plans Phase 2/3 study in 2027</p></li></ul><p><span>Outlook</span></p><ul><li><p>Tonix expects cash reserves to fund operations into Q1 2027</p></li><li><p>Tonmya launch set for November 2025 with commercial infrastructure in place</p></li><li><p>Company plans to initiate TNX-4800 study during tick season in 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>Research and development expenses for the three months ended September 30, 2025 were $9.3 million, compared to $9.1 million for the same period in 2024.</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$32.01 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$33.07 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Tonix Pharmaceuticals Holding Corp is $68.00, about 75% above its November 7 closing price of $17.00</p></li></ul><p>Press Release: <span>ID:nGNX6KCDn</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tonix Pharmaceuticals Q3 net loss widens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTonix Pharmaceuticals Q3 net loss widens\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-11 05:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Tonix Pharmaceuticals Q3 net loss widens </title></head><body><p><span>Overview</span></p><ul><li><p>Tonix Q3 net loss widens to $32 mln</p></li><li><p>Company to launch Tonmya for fibromyalgia in November, first new treatment in 15 years</p></li><li><p>Tonix in-licenses TNX-4800 for Lyme disease, plans Phase 2/3 study in 2027</p></li></ul><p><span>Outlook</span></p><ul><li><p>Tonix expects cash reserves to fund operations into Q1 2027</p></li><li><p>Tonmya launch set for November 2025 with commercial infrastructure in place</p></li><li><p>Company plans to initiate TNX-4800 study during tick season in 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>Research and development expenses for the three months ended September 30, 2025 were $9.3 million, compared to $9.1 million for the same period in 2024.</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$32.01 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$33.07 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Tonix Pharmaceuticals Holding Corp is $68.00, about 75% above its November 7 closing price of $17.00</p></li></ul><p>Press Release: <span>ID:nGNX6KCDn</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TNXP","symbol_name":"Tonix Pharmaceuticals Holding Co","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nL1N3WM13Q:1","article_id":"2582388748","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582388748","pubTimestamp":1762809948,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tonix Pharmaceuticals Q3 net loss widensOverviewTonix Q3 net loss widens to $32 mlnCompany to launch Tonmya for fibromyalgia in November, first new treatment in 15 yearsTonix in-licenses TNX-4800 for ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TNXP":"Tonix Pharmaceuticals Holding Co","BK4583":"猴痘概念","BK4139":"生物科技"},"translate_title":"Tonix Pharmaceuticals第三季度净亏损扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNXP":0.9},"content_text":"Tonix Pharmaceuticals Q3 net loss widens OverviewTonix Q3 net loss widens to $32 mlnCompany to launch Tonmya for fibromyalgia in November, first new treatment in 15 yearsTonix in-licenses TNX-4800 for Lyme disease, plans Phase 2/3 study in 2027OutlookTonix expects cash reserves to fund operations into Q1 2027Tonmya launch set for November 2025 with commercial infrastructure in placeCompany plans to initiate TNX-4800 study during tick season in 2027Result DriversResearch and development expenses for the three months ended September 30, 2025 were $9.3 million, compared to $9.1 million for the same period in 2024.Key DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income-$32.01 mlnQ3 Operating Income-$33.07 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the pharmaceuticals peer group is \"buy\"Wall Street's median 12-month price target for Tonix Pharmaceuticals Holding Corp is $68.00, about 75% above its November 7 closing price of $17.00Press Release: ID:nGNX6KCDnFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582388748","isCrawlerRequest":true}